Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Challenging Results

Calithera Reports Phase 2 CANTATA Trial of Telaglenastat for Advanced Renal Cell Carcinoma Fails to Reach Primary Endpoint

Calithera Biosciences announced topline results from the CANTATA clinical study, which was designed to evaluate the company’s glutaminase inhibitor telaglenastat […]

Calithera Reports Phase 2 CANTATA Trial of Telaglenastat for Advanced Renal Cell Carcinoma Fails to Reach Primary Endpoint
2 months ago
Share

Eli Lilly’s Monoclonal Antibody Takes a Hit: Bamlanivimab Fails Part of ACTIV-3 Trial: Greater Challenges Ahead?

As TrialSite has reported, Lilly’s Bamlanivimab (or LY-CoV555), despite its hi-tech nature as a monoclonal antibody therapy for COVID-19 with […]

Eli Lilly’s Monoclonal Antibody Takes a Hit Bamlanivimab Fails Part of ACTIV-3 Trial Greater Challenges Ahead
2 months ago
Share

Changhua County Public Health & National Taiwan University Violated Ethics Laws Starting COVID-19 Study Prior to IRB Approval

A clinical trial investigating COVID-19 antibodies conducted by the Changhua County Public Health Bureau and National Taiwan University in Taiwan […]

Changhua County Public Health & National Taiwan University Violated Ethics Laws Starting COVID-19 Study Prior to IRB Approval
3 months ago
Share

Despite Failing to Reach Endpoint in Phase 3 ALS Study, Brainstorm Plans to Move Forward with Development of NurOwn Stem Cells

Brainstorm Cell Therapeutics reported topline results from a Phase 3 trial evaluating NurOwn (MSC-NTF cells) as a treatment for Amyotrophic […]

Despite Failing to Reach Endpoint in Phase 3 ALS Study, Brainstorm Plans to Move Forward with Development of NurOwn Stem Cells
4 months ago
Share

World Health Organization Panel: Do Not Recommend Remdesivir for COVID-19 Patients Under Any Circumstances

The World Health Organization (WHO) advises against using Remdesivir under any circumstances. Apparently, a prominent group of intensive care doctors […]

World Health Organization Panel Do Not Recommend Remdesivir for COVID-19 Patients Under Any Circumstances
4 months ago
Share

Revance’s DaxibotulinumtoxinA for Injection Does Not Meet Endpoints in Phase 2 Plantar Fasciitis Trial

Revance Therapeutics reported results from its Phase 2 clinical trial of DaxibotulinumtoxinA for Injection for the management of plantar fasciitis, […]

Revance’s DaxibotulinumtoxinA for Injection Does Not Meet Endpoints in Phase 2 Plantar Fasciitis Trial
4 months ago
Share

Jounce Therapeutics Discontinues EMERGE Trial Evaluating Vopratelimab Combined with Bristol Myers Squibb’s Yervoy in Non-Small Cell Lung Cancer

Jounce Therapeutics announced the phase 2 EMERGE trial will be discontinued following early evaluation of clinical data. The open label […]

Jounce Therapeutics Discontinues EMERGE Trial Evaluating Vopratelimab Combined with Bristol Myers Squibb’s Yervoy in Non-Small Cell Lung Cancer
4 months ago
Share

Aurinia Announces Topline Data from Phase 2/3 AUDREY Trial: Voclosporin Ophthalmic Solution (VOS) Fails to Meet Endpoints in Dry Eye Syndrome

Aurinia Pharmaceuticals announced topline data from the Phase 2/3 AUDREY trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment […]

Aurinia Announces Topline Data from Phase 23 AUDREY Trial Voclosporin Ophthalmic Solution (VOS) Fails to Meet Endpoints in Dry Eye Syndrome
4 months ago
Share

Catabasis Reports Edasalonexent Fails to Achieve Primary Endpoint in Phase 3 Duchenne Muscular Dystrophy Trial

Catabasis Pharmaceuticals announced top-line results from the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The trial […]

Catabasis Reports Edasalonexent Fails to Achieve Primary Endpoint in Phase 3 Duchenne Muscular Dystrophy Trial
4 months ago
Share

University of Washington & Bill & Melinda Gates Foundation Study Leads to Conclusion: Hydroxychloroquine Not Effective in Preventing SARS-CoV-2 Infection

A recent study out of University of Washington School of Medicine in Seattle further weakens the case for hydroxychloroquine as […]

University of Washington & Bill & Melinda Gates Foundation Study Leads to Conclusion Hydroxychloroquine Not Effective in Preventing SARS-CoV-2 Infection
4 months ago
Share

Posts navigation

Older posts
Newer posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.